Tvardi Therapeutics to Present Phase 1 Trial Data of STAT3 Inhibitor TTI-101 at ASCO 2023
Tvardi Therapeutics, Inc. will publicly present clinical results from the Phase 1 study of TTI-101, a STAT3 inhibitor, for the first time at the American Society of Clinical Oncology (ASCO) 2023 annual meeting. The presentation will take place from June 2-6, 2023, in Chicago, IL, and will highlight the safety, tolerability, and clinical activity of TTI-101 monotherapy in relapsed/refractory patients with advanced solid tumors.
Details of the presentation include:
- Title and Link: Phase 1 Clinical Trial Evaluating TTI-101, a First-in-Class, Orally Bioavailable, Small Molecule, Inhibitor of STAT3, in Patients with Advanced Solid Tumors
- Session Type/Title: Poster Discussion Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
- Poster Session Display Date and Time: June 3, 2023, 8:00 AM-11:00 AM
- Poster Board Number: 216
- Poster Discussion Session Date and Time: June 3, 2023, 1:15 PM-2:45 PM
- Presenter: Apostolia M. Tsimberidou, M.D., Ph.D.
- Abstract number for publication: 3018
Imran Alibhai, PhD, CEO of Tvardi, expressed excitement about sharing the promising clinical activity of TTI-101 in patients with advanced disease, highlighting the potential for targeting STAT3 in ongoing Phase 2 trials in liver cancer, breast cancer, and idiopathic pulmonary fibrosis. The company is grateful to the patients who participated in the Phase 1 trial.
The ASCO annual meeting is the largest gathering of its kind, attracting over 40,000 attendees from various sectors of the oncology community worldwide.
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule inhibitors of STAT3, a protein crucial for cancer cell survival and immune evasion, as well as in inflammatory and fibrotic diseases. The company has completed its first-in-man Phase 1 trial of TTI-101 in patients with advanced solid tumors and has initiated three Phase 2 clinical programs in hepatocellular carcinoma, metastatic breast cancer, and idiopathic pulmonary fibrosis.